Evidence map›Paper›PMID 24818610›Full record

ArticlePloS one2014

Histone deacetylase inhibitor treatment increases coronary t-PA release in a porcine ischemia model.

Kristina Svennerholm, Niklas Bergh, Pia Larsson, Sverker Jern, Göran Johansson, Björn Biber, Michael Haney

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. The Role of Histone Protein Acetylation in Regulating Endothelial Function.Frontiers in cell and developmental biology · 2021
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kristina SvennerholmAnesthesiology and Intensive Care Medicine, Institute of Clinical Science, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Niklas BerghThe Wallenberg Laboratory for Cardiovascular Research, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Pia LarssonThe Wallenberg Laboratory for Cardiovascular Research, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Sverker JernThe Wallenberg Laboratory for Cardiovascular Research, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Göran JohanssonAnesthesiology and Intensive Care Medicine, Institute for Surgical and Perioperative Science, Umeå University, Umeå, Sweden.
Björn BiberAnesthesiology and Intensive Care Medicine, Institute of Clinical Science, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Michael HaneyAnesthesiology and Intensive Care Medicine, Institute for Surgical and Perioperative Science, Umeå University, Umeå, Sweden.
University of Gothenburg · SEUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe expression of the tissue plasminogen activator gene can be affected by histone deacetylation inhibition and thus appears to be under epigenetic control.

objectivesThe study aimed to test if in vivo pharmacological intervention by valproic acid treatment would lead to increase in tissue plasminogen activator release capacity.

methodsIn an anaesthetized pig model, a controlled transient coronary occlusion was used to stimulate coronary tissue plasminogen activator release in a valproic acid treated (one week) and a non-treated group. Coronary venous blood samples from the ischemic region were collected, great cardiac vein thermodilution flow measurements were performed, and trans-coronary tissue plasminogen activator fluxes were calculated. Plasminogen activator inhibitor-1 was also measured.

resultsAdequate sampling from the affected area after the 10 minute ischemic period was confirmed by lactate measurements. Fluxes for tissue plasminogen activator at minutes 1, 3, 5, 7 and 10 were measured and then used to present cumulative net tissue plasminogen activator release for the whole measurement period for both groups. Area under the curve was higher for the valproic acid treated group at 10 minutes; 932 ± 173 nanograms (n = 12) compared to the non-treated group, 451 ± 78 nanograms (n = 10, p = 0.023). There was no difference in levels of plasminogen activator inhibitor-1 between groups.

conclusionsThese findings support a proof of concept for histone deacetylation inhibition positive effect on tissue plasminogen activator expression in an in vivo setting. Further studies are needed to find an optimal way to implement histone deacetylation inhibition to achieve desired clinical changes in tissue plasminogen activator expression.

Indexed as

AnimalsDisease Models, AnimalEpigenesis, GeneticHistone Deacetylase InhibitorsMyocardial IschemiaMyocardiumSwineTissue Plasminogen ActivatorValproic AcidHistone Deacetylase InhibitorsTissue Plasminogen ActivatorValproic Acid

Identifiers

PMID24818610
PMCPMC4018339
OpenAlexW2043019139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.